TWI745271B - 全身紅斑性狼瘡之治療 - Google Patents

全身紅斑性狼瘡之治療 Download PDF

Info

Publication number
TWI745271B
TWI745271B TW104115791A TW104115791A TWI745271B TW I745271 B TWI745271 B TW I745271B TW 104115791 A TW104115791 A TW 104115791A TW 104115791 A TW104115791 A TW 104115791A TW I745271 B TWI745271 B TW I745271B
Authority
TW
Taiwan
Prior art keywords
compound
drug
sle
administration
dose
Prior art date
Application number
TW104115791A
Other languages
English (en)
Chinese (zh)
Other versions
TW201622728A (zh
Inventor
彼得Ｈ 沙佛
雷 吳
瑩 葉
Original Assignee
美商西建公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西建公司 filed Critical 美商西建公司
Publication of TW201622728A publication Critical patent/TW201622728A/zh
Application granted granted Critical
Publication of TWI745271B publication Critical patent/TWI745271B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW104115791A 2014-05-19 2015-05-18 全身紅斑性狼瘡之治療 TWI745271B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462000428P 2014-05-19 2014-05-19
US62/000,428 2014-05-19
US201462053626P 2014-09-22 2014-09-22
US62/053,626 2014-09-22

Publications (2)

Publication Number Publication Date
TW201622728A TW201622728A (zh) 2016-07-01
TWI745271B true TWI745271B (zh) 2021-11-11

Family

ID=53268937

Family Applications (2)

Application Number Title Priority Date Filing Date
TW104115791A TWI745271B (zh) 2014-05-19 2015-05-18 全身紅斑性狼瘡之治療
TW110125851A TWI794885B (zh) 2014-05-19 2015-05-18 全身紅斑性狼瘡之治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110125851A TWI794885B (zh) 2014-05-19 2015-05-18 全身紅斑性狼瘡之治療

Country Status (6)

Country Link
US (5) US10245266B2 (https=)
EP (1) EP3145513B1 (https=)
JP (3) JP2017522270A (https=)
ES (1) ES2969532T3 (https=)
TW (2) TWI745271B (https=)
WO (1) WO2015179276A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
NZ727295A (en) 2012-08-09 2018-06-29 Celgene Corp Treatment of immune-related and inflammatory diseases
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US10245266B2 (en) 2014-05-19 2019-04-02 Celgene Corporation 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
AU2019351811B2 (en) 2018-10-01 2025-01-02 Celgene Corporation Combination therapy for the treatment of cancer
AR123650A1 (es) * 2020-10-02 2022-12-28 Celgene Corp Métodos para el tratamiento del lupus eritematoso sistémico y el uso de biomarcadores como un predictor de sensibilidad clínica a terapias
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
EP1064277B1 (en) 1998-03-16 2005-06-15 Celgene Corporation 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
GB0120441D0 (en) 2001-08-22 2001-10-17 Novartis Forschungsstiftung Model of autoimmune disease and methods for identifying anti autoimmune disease disorders
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
AU2007249805B2 (en) 2006-05-12 2013-01-10 University Of Miami Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma
US20080045485A1 (en) 2006-08-17 2008-02-21 Peter Muir Methods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture
SG177221A1 (en) 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
KR101791757B1 (ko) 2007-03-20 2017-10-30 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
WO2008119170A1 (en) 2007-03-30 2008-10-09 Chu Sainte Justine Method of determining risk of scoliosis
JP5442185B2 (ja) 2007-04-24 2014-03-12 日本メナード化粧品株式会社 感作性物質評価方法
WO2009124064A1 (en) 2008-03-31 2009-10-08 Boston Medical Center Corporation Predictive marker for topoisomerase i inhibitors
EP2274617A4 (en) 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
HUE029289T2 (en) 2008-12-05 2017-02-28 Abbvie Inc Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases
KR101787768B1 (ko) 2009-04-18 2017-10-18 제넨테크, 인크. 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
TWI509247B (zh) * 2010-03-12 2015-11-21 西建公司 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記
JP2013540995A (ja) 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 疾患に対する循環バイオマーカー
WO2012115885A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
US9730941B2 (en) * 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
ES2872967T3 (es) * 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9371568B2 (en) * 2012-07-31 2016-06-21 Novartis Ag Markers associated with human double minute 2 inhibitors
NZ727295A (en) * 2012-08-09 2018-06-29 Celgene Corp Treatment of immune-related and inflammatory diseases
US20140343058A1 (en) 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
UA117141C2 (uk) * 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
US10245266B2 (en) * 2014-05-19 2019-04-02 Celgene Corporation 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Also Published As

Publication number Publication date
US11660302B2 (en) 2023-05-30
US20190262348A1 (en) 2019-08-29
EP3145513B1 (en) 2023-11-15
TWI794885B (zh) 2023-03-01
US10596179B2 (en) 2020-03-24
ES2969532T3 (es) 2024-05-21
US20220008427A1 (en) 2022-01-13
WO2015179276A1 (en) 2015-11-26
JP2020143083A (ja) 2020-09-10
EP3145513A1 (en) 2017-03-29
JP2022058443A (ja) 2022-04-12
US20170173029A1 (en) 2017-06-22
US10245266B2 (en) 2019-04-02
TW202216156A (zh) 2022-05-01
US20200360396A1 (en) 2020-11-19
US10980812B2 (en) 2021-04-20
JP2017522270A (ja) 2017-08-10
TW201622728A (zh) 2016-07-01
US20240041894A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
TWI745271B (zh) 全身紅斑性狼瘡之治療
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
US20230159490A1 (en) Treatment of immune-related and inflammatory diseases
US20140343058A1 (en) Treatment of systemic lupus erythematosus
TW202345799A (zh) Ｔｙｋ２抑制劑及其用途
US12016836B2 (en) Compositions and methods for reducing immune intolerance and treating autoimmune disorders
US20180318300A1 (en) Treatment of autoimmune disease
TWI888486B (zh) 用於治療發炎疾病之新穎藥物
WO2015179279A1 (en) Treatment of immune-related and inflammatory diseases
HK1232801B (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
BR112017020591B1 (pt) Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2- trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina
CN118973583A (zh) Tyk2抑制剂及其用途
US20250120956A1 (en) Azole Compounds for Enhancing Telomerase Reverse Transcriptase (TERT) Expression
TW202604500A (zh) 用於治療發炎疾病之新穎藥物